Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dosage recommendations for teicoplanin.

Literature DB >> 8144419

Dosage recommendations for teicoplanin.

A P Wilson¹, R N Grüneberg, H Neu.

Abstract

Entities: Chemical

Mesh：

Substances：
Teicoplanin

Year: 1993 PMID： 8144419 DOI： 10.1093/jac/32.6.792

Source DB: PubMed Journal: J Antimicrob Chemother ISSN： 0305-7453 Impact factor: 5.790

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

Review 1. Current perspectives on glycopeptide resistance.

Authors: N Woodford; A P Johnson; D Morrison; D C Speller
Journal: Clin Microbiol Rev Date: 1995-10 Impact factor: 26.132

Review 2. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors: C M Spencer; H M Bryson
Journal: Pharmacoeconomics Date: 1995-04 Impact factor: 4.981

3. Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.

Authors: D P Nicolau; M N Marangos; C H Nightingale; K B Patel; B W Cooper; R Quintiliani; P Courvalin; R Quintiliani
Journal: Antimicrob Agents Chemother Date: 1996-01 Impact factor: 5.191

Review 4. A risk-benefit assessment of teicoplanin in the treatment of infections.

Authors: F de Lalla; A Tramarin
Journal: Drug Saf Date: 1995-11 Impact factor: 5.606

5. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Authors: Federico Pea; Pierluigi Viale; Anna Candoni; Federica Pavan; Leonardo Pagani; Daniela Damiani; Marco Casini; Mario Furlanut
Journal: Clin Pharmacokinet Date: 2004 Impact factor: 6.447

10. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus.

Authors: H J Schaad; C Chuard; P Vaudaux; F A Waldvogel; D P Lew
Journal: Antimicrob Agents Chemother Date: 1994-08 Impact factor: 5.191

Dosage recommendations for teicoplanin.

Review 1. Current perspectives on glycopeptide resistance.

Review 2. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

3. Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.

Review 4. A risk-benefit assessment of teicoplanin in the treatment of infections.

5. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Review 6. Teicoplanin: 10 years of clinical experience.

Review 7. Anti-infective treatment in intensive care: the role of glycopeptides.

8. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers.

Review 9. Use of teicoplanin in community medicine.

10. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus.